Aimovig is a brand name for erenumab, a prescription medication used for the preventive treatment of migraine headaches in adults. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. Aimovig works by blocking the activity of CGRP, a molecule involved in migraine attacks, thus reducing the frequency and severity of migraines.
Aimovig is primarily used for the preventive treatment of migraines in adults. It helps reduce the frequency and severity of migraine attacks, allowing individuals to experience fewer debilitating headaches.
The safety of Aimovig in pregnant women and children has not been established. It is important to consult with a healthcare professional before using Aimovig if you are pregnant or planning to become pregnant, or if you are considering giving it to a child.
There have been no recalls of Aimovig reported to date. It is important to always check with your healthcare provider or the FDA for any updated information on recalls or safety concerns.
Aimovig received FDA approval in May 2018 for the preventive treatment of migraines in adults. This approval was based on clinical trials that demonstrated the effectiveness of Aimovig in reducing the frequency of migraine attacks.
Aimovig is prescribed to individuals who suffer from frequent migraines and are in need of preventive treatment. It is typically recommended for those who have not responded well to other migraine medications or have experienced intolerable side effects.
Aimovig is administered as a subcutaneous injection once a month. It comes in a pre-filled autoinjector or a pre-filled syringe that can be self-administered after proper training from a healthcare professional. It is important to follow the instructions provided by your healthcare provider and not exceed the recommended dosage.
Currently, Aimovig is only approved for the preventive treatment of migraines in adults. It is not intended for the treatment of acute migraines or other types of headaches.
Before using Aimovig, it is important to inform your healthcare provider about any existing medical conditions or allergies you may have. Additionally, let them know about any medications you are currently taking, as they may interact with Aimovig.
Aimovig should be stored in the refrigerator between 36°F to 46°F (2°C to 8°C). It should not be frozen. If necessary, it can be stored at room temperature (up to 77°F or 25°C) for up to 7 days. Aimovig should be kept out of the reach of children and pets. Unused or expired Aimovig should be disposed of properly according to local regulations.
In case of an emergency or overdose of Aimovig, it is important to seek immediate medical attention. Contact your local poison control center or go to the nearest emergency room for assistance.
It is important to attend regular check-ups with your healthcare provider while using Aimovig to monitor its effectiveness and any potential side effects. Aimovig is not a cure for migraines, but it can significantly reduce their frequency and severity.
Like any medication, Aimovig carries some risks. However, when used as prescribed and under the supervision of a healthcare professional, the benefits of Aimovig generally outweigh the potential risks. It is essential to discuss any concerns or questions you may have with your healthcare provider before starting Aimovig treatment.
Remember, this article is for informational purposes only and should not replace the advice of a healthcare professional. Always consult with your doctor or pharmacist for personalized guidance on the use of Aimovig or any other medication.